Market Size (2016)
2016
$8.13B
Healthcare
PEGylated Drugs Market
By Segment, By Region, And Segment Forecasts, 2016 – 2025
Vertical: HealthcareBase Year: 201812 Sections
Executive Summary
PEGylated Drugs Market — Snapshot
Projected (2025)
2025
$13.50B
CAGR (2016–2025)
5.8%
5.8%Key Players
108+
PEGylated drugs are a novel drug delivery technology and offer several advantages such as reduced proteolytic degradation along with minimized immunogenicity which improves the therapeutic efficacy of drugs. The molecules such as proteins, peptides, enzymes, antibody fragments, oligonucleotides, and others are modified by attaching the polymeric chains of ethylene glycol. The process of adding the ethylene glycol is known as PEGylation. The PEGylation of the molecules increases the bioavailability of drugs during the pharmacological process. The PEGylated drugs exhibit remarkably more efficient effect toward the intended use to treat respective indications.
The increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancement in the biologics sector are expected to have a positive impact on the growth of the global PEGylated drugs market. However adverse drug reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drug market during the assessment period.
The global PEGylated drug market was valued at USD 9,285.64 million in 2018 and is estimated to be valued at USD 13,503.67 million by 2025 and register a CAGR of 5.53% during the forecast period. In 2018, the Americas accounted for the largest market share of 65.73% with a market value of USD 6,103.30 million, followed by Europe with a market value of USD 1,507.66 million in 2018.
The global PEGylated drugs market has been segmented based on molecule and indication.
Based on molecule, the protein segment accounted for the largest market share of 64.80% in 2018, with a market value of USD 6,017.50 million, and is projected to register a CAGR of 5.84% during the forecast period. On basis of indication, the cancer segment accounted for the largest market share of 62.46% in 2018, with a market value of USD 5,799.52 million, and is anticipated to register a CAGR of 6.10% during the review period.
Key Insight
The PEGylated Drugs Market market is projected to grow at a CAGR of 5.8% from 2016 to 2025.
Market Performance Trend
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Scope & Coverage
What this report covers
- Geographic Coverage: This analysis covers 4 regions: Middle East and Africa, Americas, Asia Pacific, Europe.
- Market Segmentation: The market is analyzed across 5 segments: Cancer, Indication_Others, Gout, Hemophilia, Hepatitis. Forecasts are provided for each segment from 2016 to 2025.
- Competitive Landscape: 108 leading companies are profiled, covering market positioning, strategies, and recent developments.
Market Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Overview
PEGylated Drugs Market — Growth Trajectory
PEGylation refers to the modification of biological molecules by covalent conjugation with polyethylene glycol. PEGylation is a well-established technology for improving the therapeutic value of drug molecules such as enzymes, antibody fragment, and aptamers. PEGylated drugs offer several advantages such as reduced proteolytic degradation along with minimized immunogenicity which improves the therapeutic efficacy of drugs.
PEGylated Drugs Market — Growth Trajectory
Cancer
Indication_Others
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size Trend (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Dimensions
How this market is segmented
- Molecule Molecule is broken down into: Protein, FAB’ fragment, Enzyme, Aptamer, Others.
- Indication Indication is broken down into: Cancer, Gout, Hemophilia, Hepatitis, Indication_Others.
Geographic Analysis
Regional market breakdown
- Middle East and Africa Middle East and Africa market size reached $294.33M in 2016 and is projected to reach $466.65M by 2025, growing at a CAGR of 5.3%.
- Americas Americas market size reached $5.36B in 2016 and is projected to reach $8.80B by 2025, growing at a CAGR of 5.7%.
- Asia Pacific Asia Pacific market size reached $1.16B in 2016 and is projected to reach $2.02B by 2025, growing at a CAGR of 6.4%.
- Europe Europe market size reached $1.31B in 2016 and is projected to reach $2.22B by 2025, growing at a CAGR of 6.0%.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansResearch Methodology
PEGylated Drugs Market — How We Researched This Market
This report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Research Process
Historical data (2016–2018) and forecast period (2018–2025)
1
Problem Definition
- Market scoping
- Objective setting
- Framework design
2
Secondary Research
- Literature review
- Data mining
- Trend analysis
3
Primary Research
- Expert interviews
- Field visits
- Surveys
4
Data Analysis
- Quantitative modeling
- Statistical testing
- Validation
5
Insights & Reporting
- Synthesis
- Recommendations
- Visualization
Research Depth
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Historical vs. Forecast Data
Historical (observed)
Forecast (modelled)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCompetitive Landscape & Porter's Five Forces
PEGylated Drugs Market — Competitive Analysis
THREAT OF NEW ENTRANTS
Threat from a new entrant is considered to have a moderate impact on the industry. In Porter’s Five Forces Analysis, ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry is more likely to attract competitors looking to achieve higher profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. Any new or novel treatment has to be better at the existing first-line drugs. The existing treatments are fraught with serious side-effects and their low cure rates. Thus, the emergence of a novel acting treatment will lead to faster market absorption with the least market uptake costs. The rising application of PEGylated drugs for the treatment of chronic diseases such as cancers arthritis, gout, and others. The major companies have rigorously invested in R&D of PEGylated drugs and have a good number of molecules in the pipeline. For instance, in 2018 Coherus BioSciences, Inc introduced pegfilgrastim-cbqv (Udenyca) second biosimilar to the reference drug Neulasta by Amgen, Inc. Hence the overall threat of new entrants in the global PEGylated drugs market is moderate to high.
BARGAINING POWER OF SUPPLIERS
The suppliers in the global PEGylated drugs market are the raw material providers. There are several raw material providers in the market for the developments of different products. Due to the complexity of the process, quality requirements, and the government regulations on the drugs formulations; the bargaining power of suppliers is high in the market. Currently, most of the approved drugs are related to specific diseases and disorders. Strategic and economic modifications of the existing PEGylated drugs can have a huge impact on the market with the other pharmaceutical, biotechnological companies, and device manufacturing companies being involved in the business. Hence the overall bargaining power of suppliers in the global PEGylated drugs market is moderate to high.
BARGAINING POWER OF BUYERS
The bargaining power of the buyers is considered to have a high impact on the industry. The bargaining power of the buyers assesses how easy it is for the buyers to affect the price of PEGylated drugs. The large customer base ensures the possibility of the high demand of PEGylated drugs by large hospitals and healthcare providers. As there are available options in the market and the offer attractive prices for their products, thus the price sensitivity for PEGylated drugs is high in the market.
THREAT OF SUBSTITUTES
The threat of substitutes in the global PEGylated drugs is very high. High threat of substitutes is due to the massive research and funding conducted to develop technologically advanced treatments by market players. PEGylated drugs have been used for various therapies for a considerable number of years and are proving its efficiency. For example, targeted therapies and hormonal therapies have witnessed majority usage. Thus, the threat of substitutes of PEGylated drugs is high.
INTENSITY OF RIVALRY
The degree of competition in the global PEGylated drugs market is high. There is a large number of players in the market at present, and their product portfolio is quite varied from one another. The major companies are trying to develop accurate drugs to capture the major chunk of the market. Hence the level of intensity of rivalry is high. To overcome the competition, players are engaged in partnering with the established pharmaceuticals. Moreover, the players are also developing advanced products to differentiate their brand from competitors.
Quantitative Analysis
Regional Breakdown
Regional market breakdown for PEGylated Drugs Market.
Regional Market Size (USD Mn)
Market estimates by geography (2025)
USD Mn
InsightAmericas leads with $8.80B by 2025, while Asia Pacific is projected to grow fastest at a 6.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansRegional Market Data
| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $294.33M | $388.27M | $466.65M | 5.3% | 3% |
| Americas | $5.36B | $7.15B | $8.80B | 5.7% | 65% |
| Asia Pacific | $1.16B | $1.60B | $2.02B | 6.4% | 15% |
| Europe | $1.31B | $1.78B | $2.22B | 6.0% | 16% |
| Total | $8.13B | $10.92B | $13.50B | 5.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSegment Revenue (2025)
Cancer
Indication_Others
Gout
Hemophilia
Hepatitis
02404480872119615
Segment Market Share
- Cancer65%
- Indication_Others27%
- Gout4%
- Hemophilia2%
- Hepatitis2%
Total Market Size
$13.50B
Market by Segment (2025)
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cancer | $8.74B | 5.8% | 53% |
| Indication_Others | $3.65B | 5.8% | 88% |
| Gout | $568.44M | 5.8% | 77% |
| Hemophilia | $293.87M | 5.8% | 67% |
| Hepatitis | $254.09M | 5.8% | 60% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansEmpower your Business
with InsightsSave over 20% on
with Insights
Save over 20% on
Annual Subscription
See plans for professionals or small and medium businesses.
Analytics
PEGylated Drugs Market — Key Findings
Analytical insights on PEGylated Drugs Market covering market dynamics, competitive landscape, and strategic outlook.
Key Analytical Findings
The PEGylated Drugs Market market is projected to reach $13.50B by 2025, growing at 5.8% CAGR. The Cancer segment holds the largest share.
Market Dynamics
PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to increase the therapeutic efficacy of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings.
The global PEGylated drugs market is emerging due to the increase in the prevalence of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector.
However, adverse reactions associated with PEGylated drugs and drug recalls are hampering the growth of the market.
Market Drivers
The burden of chronic diseases, including cancer, is rising. Globally, the prevalence of various types of cancer is increasing. According to the World Cancer Research Fund International, in 2015, cancer was responsible for 8.8 million deaths. Globally, about one in six deaths are found due to cancer.
Moreover, according to the National Cancer Institute, in 2016, 15.5 million new cases of cancer were registered, and approximately USD 147.3 billion were spent for cancer care in the US. It also reported that the number of new cases of cancer per year is expected to rise to 23.6 million by 2030 in the US. According to the Canadian Cancer Society, an estimated 206,200 new cases of cancer and 80,800 deaths occurred in Canada in 2017. Additionally, the Office for National Statistics reported over 65.3% of total cancers in adults aged 65 years in the UK in 2016. Furthermore, according to the Cancer Research UK, the four most common cancers occurring worldwide are lung, female breast, bowel, and prostate cancer. This rising prevalence of cancer is creating a demand for effective drugs. The use of advanced drug delivery system with PEGylation technology is significant in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to boost the growth of the global PEGylated drugs market.
Market Opportunities
The growing demand for PEGylated drugs and lucrative growth opportunities have strived the participants of the biopharmaceutical industry to engage in R&D to manufacture innovative drug candidates. For instance, UCB and Biogen are evaluating the safety and efficacy of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is being developed for the treatment of systemic lupus erythematosus. Moreover, Horizon Therapeutics PLC has numerous drugs in the pipeline, such as HZN-003. The drug is still in the preclinical phase and is designed for the treatment of rheumatic diseases.
The development of these new drugs is likely to boost the global PEGylated drugs market in the near future. Apart from this, other companies such as Hoffman-La Roche AG and Takeda, are involved in the development of various PEGylated drugs. Majority of the drugs in the pipeline are currently developed for the market in developed regions such as the US and Europe. However, this creates huge opportunities for key players to invest in the Middle Eastern and African region after the approval of pipeline products in the EU and the US.
Market Restraints
PEGylation is an established technique that can be effective in prolonging blood circulation with improved drug solubility and stability. Apart from this, PEGylated drugs also have side-effects associated with the treatment. The attachment of Polyethylene Glycol (PEG) with drugs, however, comes with certain limitations. In some cases, intravenous administration results in hypersensitivity reactions and blood clots. In other cases, it results in antibody production in the body and also shows hypersensitivity reactions when administered with laxatives. The adverse drug reactions associated with PEGylated drugs could hamper the growth of the market.
Strategic Outlook and Future Directions
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Market Value by Segment (2025)
Value (USD Mn)
Cancer
Indication_Others
Gout
Hemophilia
Hepatitis
Companies
Key companies profiled in PEGylated Drugs Market
Profiles of 108 companies operating in the PEGylated Drugs Market market, including revenue, employee count, and market positioning where available.
Showing 108 of 108 companies
Takeda Pha
Takeda Pharmaceutical Company Limited
Healthcare
Company Headquarters: Japan Founded: 1925 Workforce: ~ 47,347 Company Working: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs, and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases, and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Revenue$30.3B
Employees47,347
Market CapN/A
Founded1924
Japan
AstraZenec
AstraZeneca
Healthcare
Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.
Revenue$21.0B
Employees83,100
Market CapN/A
Founded1998
Cambridge, UK
UCB S.A.
UCB S.A.
Healthcare
Company Headquarters: Brussels, Belgium Founded: 1928 Workforce: ~7,495 Company Working: UCB S.A.(UCB) is among the biopharmaceutical companies that are driven by innovation and development. The company’s business operates through its manufacturing, selling, and distributing of biopharmaceutical solutions. UCB has its presence in various geographic locations around the Americas, Europe, and others. It has products under the pipeline, and it has filed its two molecules for approval.
Revenue$5.4B
Employees7,495
Market CapN/A
Founded1927
Brussels, Belgium
Novo Nordi
Novo Nordisk A/S
Healthcare
Company Headquarters: Bagsværd, Denmark Founded: 1923 Workforce: ~43,258 Company Working: Novo Nordisk A/S (Novo Nordisk) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. The company’s operating segments are diabetes, hemophilia, growth disorders, obesity, and other biopharmaceuticals. The company has research and development centers in China, India, Denmark, the UK, and the US. It has a strong clinical pipeline of drugs for conditions such as Type 1 diabetes, Type 2 diabetes, obesity, atherosclerosis, and hemophilia and growth disorders. The company operates in 79 countries and markets its products in more than 170 countries.
Revenue$16.3B
Employees43,258
Market CapN/A
Founded1922
Bagsværd, Denmark
Horizon Th
Horizon Therapeutics PLC
Healthcare
Company Headquarters: Dublin, Ireland Founded: 2008 Workforce: ~1,000 Company Working: Horizon Therapeutics PLC (Horizon) was formerly knowns as Horizon Pharma PLC. In May 2019 the company changed its name from Horizon Pharma PLC to Horizon Therapeutics PLC. The company believes that the new name reflects its strategy and obligation towards patient care. It is operational in the US, Europe, and other locations worldwide. It has products catering to a wide range of indications such as rheumatology, inflammation, and others. The company has different molecules in the pipeline, which provides it a potential business growth.
Revenue$1.0B
Employees1,000
Market CapN/A
Founded2007
Dublin, Ireland
Amgen Inc.
Amgen Inc.
Healthcare
Company Overview Company Headquarters: California, US Founded: 1980 Workforce: 20,000+ Company Working: Amgen Inc. (Amgen), a well-known biopharmaceutical company, was founded in 1860. The company focuses on discovering, developing, manufacturing, and delivering innovative human therapeutic products. It uses tools such as advanced human genetics to unravel the intricacies of diseases and understand the fundamentals of human biology. It serves its products in major therapeutic areas such as oncology, cardiovascular disease, inflammation, bone health, nephrology, and neuroscience. Amgen operates through one business segment, namely, human therapeutics. It focuses on areas that have high unmet medical needs and leverages its expertise to develop solutions for improving health outcomes and efficiently improve people's lives. It has become one of the leading independent biotechnology companies in the world.
Revenue$23.0B
Employees20,000
Market CapN/A
Founded1979
California, US
Page 1 of 18
…
Go to page
Powering the world's best teams.
From next-gen startups to established enterprises.
What our clients say
Trusted by forward-thinking businesses
for data-driven intelligence
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Noah Malgeri
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Michael Robert
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Joseph Aguayo
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Bong Lau
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Peter Groot Koerkamp
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Younghwan Choi
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Mark Irwin
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
Jason Lee
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Akif Moroglu
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
PEGylated Drugs Market
Starting from
$4,950